Small-molecule inhibitor and application of small-molecule inhibitor in inhibition of monoacylglycerol lipase

By developing small molecule inhibitors to bind to human monoacylglycerol lipase and inhibiting their activity, the problem that the prior art is difficult to effectively inhibit MGL in cancer has been solved, and effective treatment of related diseases has been achieved.

CN119055655APending Publication Date: 2024-12-03HUBEI UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310649738.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing therapeutic approaches are difficult to effectively inhibit the activity of monoacylglycerol lipase (MGL) in cancer, leading to challenges in treatment-related diseases.

Method used

A small molecule inhibitor is developed to inhibit its activity by binding to human monoacylglycerol lipase and form a composition in combination with a pharmaceutical carrier for the treatment or prevention of MGL-related diseases. The structure of the small molecule inhibitor is R-C≡N, and the dosage molar concentration ratio in the final volume of the reaction ranges from 50:1 to 100,000:1, preferably from 600:1 to 2000:1.

Benefits of technology

Small molecule inhibitors show good inhibitory effects, can effectively reduce the survival rate of tumor cells, and have great application prospects in cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055655A_ABST
    Figure CN119055655A_ABST
Patent Text Reader

Abstract

The invention discloses application of a small-molecule inhibitor to preparation of a medicine for inhibiting monoacylglycerol lipase. According to the invention, a novel small-molecule inhibitor aiming at monoacylglycerol lipase (MGL) is obtained in an experimental screening mode, and subsequent verification shows that the novel small-molecule inhibitor has good inhibitory activity, so that a potential medicine is provided for clinically treating related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to a small molecule inhibitor targeting protease and application thereof; in particular, it relates to application of a small molecule inhibitor of human monoacylglycerol lipase (MGL). Background Art

[0002] Monoglycerol lipases (MGLs) were first discovered in the rat intestine and adipose tissue. They catalyze the metabolism of extracellular and intracellular intermediates monoglycerol (MG) into free fatty acids (FA) and glycerol through the classic serine-aspartate-histidine triad catalytic mechanism. In mammals, the extracellular source of MG is dietary lipids hydrolyzed in the intestine and plasma. Intracellular MG comes from the hydrolysis of diglycerol during the degradation of triglycerides and glycerophospholipids.

[0003] MGL has also been shown to hydrolyze 2-arachidonoylglycerol, an important signaling molecule in cannabinoid metabolism within the central nervous system. The endocannabinoid system regulates various physiological processes, such as appetite, inflammation, pain perception, and memory. In addition, the role of MGL in the progression of melanoma, human breast cancer, ovarian cancer, and colorectal cancer has been confirmed. Inhibition of MGL activity in these cancers showed significant inhibition of cell proliferation, which also makes MGL a promising new drug target for the treatment of cancer, so MGL and its inhibitors are considered to have high therapeutic relevance. . Summary of the invention

[0004] In view of the above technical problems, the purpose of the present invention is to provide a small molecule inhibitor against MGL, so as to provide a potential drug for the clinical treatment of related diseases.

[0005] The technical solution provided by the present invention is as follows:

[0006] In a first aspect, the present invention provides the use of a small molecule inhibitor in the preparation of a drug for inhibiting monoacylglycerol lipase, and the structure of the small molecule inhibitor is as follows:

[0007]

[0008]

[0009] Among them, R is -C≡N.

[0010] Furthermore, the monoacylglycerol lipase is human monoacylglycerol lipase.

[0011] Furthermore, the molar concentration ratio of the small molecule inhibitor in the final reaction volume is small molecule inhibitor: protein = 50: 1 to 100000: 1. Preferably, the molar concentration ratio of the small molecule inhibitor in the final reaction volume is small molecule inhibitor: protein = 600: 1 to 2000: 1.

[0012] The present invention also provides a composition, which contains an effective amount of a small molecule inhibitor or its analog provided by the present invention for inhibiting monoacylglycerol lipase and a pharmaceutically suitable carrier. Preferably, the composition is a pharmaceutical composition, which contains an effective amount of a small molecule inhibitor or its analog provided by the present invention and a pharmaceutically suitable carrier. More preferably, the pharmaceutical composition is a pharmaceutical composition for treating or preventing a disease that responds to the inhibition of monoacylglycerol lipase (MGL), wherein the monoacylglycerol lipase (MGL) is preferably human monoacylglycerol lipase (MGL); and also includes a small molecule inhibitor or its analog provided by the present invention and a pharmaceutically suitable carrier in an effective amount for preventing and treating a disease that responds to the inhibition of monoacylglycerol lipase (MGL).

[0013] The small molecule inhibitors or their analogs of the present invention and the above-mentioned compositions can be used to inhibit monoacylglycerol lipase (MGL), preferably human monoacylglycerol lipase (MGL), wherein the inhibition is for therapeutic purposes or non-therapeutic purposes. Preferably, the small molecule inhibitors or their analogs of the present invention are used to prepare drugs for inhibiting monoacylglycerol lipase (MGL), preferably human monoacylglycerol lipase (MGL). Therefore, the present invention also provides a method for inhibiting the activity of monoacylglycerol lipase (MGL), which comprises administering an effective amount of the small molecule inhibitors or their analogs of the present invention or the above-mentioned compositions to a target object that needs to inhibit monoacylglycerol lipase (MGL), wherein the inhibition is for therapeutic purposes or non-therapeutic purposes.

[0014] The present invention also provides a method for treating a disease that responds to the inhibition of monoacylglycerol lipase (MGL), which comprises administering to an individual in need of such treatment or prevention a preventively or therapeutically effective amount of a small molecule inhibitor of the present invention or its analog or the above-mentioned composition that inhibits monoacylglycerol lipase (MGL) (preferably human monoacylglycerol lipase (MGL)).

[0015] The small molecule inhibitors or analogs thereof of the present invention can be used to prepare drugs or pharmaceutical compositions for treating diseases that respond to the inhibition of monoacylglycerol lipase, wherein monoacylglycerol lipase (MGL) or its analogs inhibit the activity of monoacylglycerol lipase, and the diseases include tumors, etc., preferably the above-mentioned tumors.

[0016] In a second aspect, the present invention provides a method for screening the above-mentioned small molecule for inhibiting MGL, and the specific steps are as follows:

[0017] 1. Construction of MGL prokaryotic gene plasmid

[0018] The MGL gene sequence was inserted into the pET-28a plasmid by restriction digestion to construct the pET28a-His-MGL plasmid, which was verified by DNA sequencing;

[0019] 2. Expression of MGL fusion protein

[0020] The plasmid constructed in step 1 was transformed into the Escherichia coli BL21 strain by the CaCl2 method, and selected by kanamycin. Then, a single colony grown on a Luria-Bertani (LB) culture plate containing kanamycin was inoculated into a liquid LB medium containing kanamycin for culture, and then collected by centrifugation;

[0021] 3. Purification of MGL fusion protein

[0022] The bacterial sludge collected in step 2 was resuspended in lysis buffer, lysed by ultrasonic method, and then the lysate was centrifuged at 4°C and 10,000 rpm, and the supernatant was retained; finally, Ni-NTA His tag protein binding filler was used for binding and purification to obtain human MGL fusion protein;

[0023] 4. Activity test of MGL protein

[0024] His-MGL protein was added to each well of the well plate and incubated at room temperature for different time periods. After the incubation time was reached, 4-NPA (p-nitrophenyl acetate) was added to each well at the same time, and the absorbance value was determined using the absorbance kinetics in an ELISA reader.

[0025] 5. Verification of inhibitor activity

[0026] His-MGL protein was added to each well of the well plate, and then small molecule solutions of different concentrations were added, and incubated at room temperature for different times; the absorbance value was determined by absorbance kinetics in an ELISA instrument, and the inhibition rate was calculated and plotted.

[0027] 6. Verification of reversible inhibitory activity

[0028] According to the system in step 5, the appropriate small molecule concentration and incubation time were selected and divided into three groups for control: the first group was tested after the single small molecule and protein were incubated for a certain period of time and then the substrate (4-NPA) was added; the second group was tested after the concentration of small molecule and protein was amplified by 50 times; the third group was tested after the remaining 10 minutes of incubation under the same incubation conditions as the second group. The absorbance value was determined by the absorbance kinetics in the microplate reader, and the inhibition rate was calculated and plotted.

[0029] 7. Preliminary verification of covalency by HPLC

[0030] According to the system in step 5, select the appropriate small molecule concentration, set the incubation time gradient, add the substrate 4-NPA after the incubation time is reached, add acetonitrile immediately after ten minutes of reaction to terminate the reaction, then filter through a filter membrane, use HPLC to determine the consumption of the substrate (4-NPA) of each sample, calculate the inhibition rate and plot it to determine whether the inhibition rate increases with the increase in incubation time, thereby determining whether it has certain covalent properties.

[0031] 8. Use CCK-8 to detect the effect of different incubation times of small molecules on the survival rate of tumor cells

[0032] Take MB231 cells in the logarithmic growth phase, and make a cell suspension after standard digestion treatment. After counting the cells, the concentration of the cell suspension is obtained, and the cells are inoculated in the well plate at different inoculation densities, and placed in a 37°C incubator for overnight adherent culture. The next day, the old culture medium in each well was discarded, and the cells were treated with culture medium containing different small molecules. The control group added DMSO in an amount equal to the small molecule, and the DMSO concentration was less than 0.1%. After drug treatment, the well plate was placed in an incubator for incubation for 48h and 72h. After the drug incubation was completed, the old culture medium in each well was aspirated, and then the culture medium containing CCK-8 (5% FBS) was added to each experimental well. Place in the incubator and continue incubation for 4h, and then use an enzyme-labeled detector to detect the absorbance value (OD value) of each well, and the measurement wavelength is 450nm. Calculate the cell survival rate (%) = (OD drug-OD blank) / (OD control-OD blank) × 100%, and plot with the cell survival rate as the ordinate and the logarithm of the drug concentration as the abscissa.

[0033] 9. Use CCK-8 to detect the effect of different concentrations of small molecules on tumor cell survival rate

[0034] Take MB231 cells in the logarithmic growth phase, and make a cell suspension after standard digestion treatment. After counting the cells, the concentration of the cell suspension is obtained, and the cells are inoculated in a well plate at a certain density and placed in a 37°C incubator for overnight adherent culture. The next day, the old culture medium in each well is discarded, and the cells are treated with culture medium (5% FBS) containing small molecules of different concentrations. The control group adds DMSO equal to the small molecule, and the DMSO concentration is less than 0.1%. After drug treatment, the well plate is placed in an incubator for 72 hours. After the drug incubation is completed, the old culture medium in each well is sucked out, and then the culture medium containing CCK-8 (5% FBS) is added to each experimental well. Place in an incubator and continue to incubate for 4 hours, and then use an enzyme-labeled detector to detect the absorbance value (OD value) of each well, and the measurement wavelength is 450nm. Calculate the cell survival rate (%) = (OD drug-OD blank) / (OD control-OD blank) × 100%, and draw a graph with the cell survival rate as the ordinate and the logarithm of the drug concentration as the abscissa.

[0035] The beneficial effects of the present invention are as follows:

[0036] The present invention provides a small molecule inhibitor for inhibiting monoacylglycerol lipase, and verification shows that the small molecule inhibitor exhibits good inhibitory effect. The molecular inhibitor and related compositions can be used to treat related cancers by inhibiting the action of MGL, have great application prospects, and are conducive to the expansion of therapeutic drugs and treatment plans. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 It is a process for testing the effect of small molecule inhibitors;

[0038] Figure 2 This is the verification of the activity of MGL protein and 4-NPA in Example 1;

[0039] Figure 3 (Top left) shows the inhibitory effects of small molecules at different concentrations and incubated for different times on MGL in Example 1; Figure 3 (Top right) is the reversible effect of the small molecule's inhibition of MGL in Example 1; Figure 3 (Lower left) is the covalent effect of the small molecule in Example 1 on the inhibition of MGL; Figure 3 (Bottom middle) shows the effect of different incubation times of small molecules on the survival rate of tumor cells in Example 1; Figure 3 (lower right) shows the effect of different concentrations of small molecules on the survival rate of tumor cells in Example 1;

[0040] Figure 4 (Top left) shows the inhibitory effects of small molecules at different concentrations and incubated for different times on MGL in Example 2; Figure 4 (Top right) is the reversible effect of the small molecule's inhibition of MGL in Example 2; Figure 4 (Lower left) is the covalent effect of the small molecule in Example 2 on the inhibition of MGL; Figure 4 (Bottom middle) shows the effect of different incubation times of small molecules on the survival rate of tumor cells in Example 2; Figure 4 (lower right) shows the effect of different concentrations of small molecules on the survival rate of tumor cells in Example 2;

[0041] Figure 5 (Top left) shows the inhibitory effects of small molecules at different concentrations and incubated for different times on MGL in Example 3; Figure 5 (Top right) is the reversible effect of the small molecule's inhibition of MGL in Example 3; Figure 5 (Lower left) is the covalent effect of the small molecule in Example 3 on the inhibition of MGL; Figure 5 (Bottom middle) shows the effect of different incubation times of small molecules on the survival rate of tumor cells in Example 3; Figure 5 (lower right) shows the effect of different concentrations of small molecules on the survival rate of tumor cells in Example 3;

[0042] Figure 6 (Top left) shows the inhibitory effects of small molecules at different concentrations and incubated for different times on MGL in Example 4; Figure 6 (Top right) is the reversible effect of the small molecule's inhibition of MGL in Example 4; Figure 6 (Lower left) is the covalent effect of the small molecule in Example 4 on the inhibition of MGL; Figure 6 (Bottom middle) shows the effect of different incubation times of small molecules on the survival rate of tumor cells in Example 4; Figure 6 (lower right) shows the effect of different concentrations of small molecules on the survival rate of tumor cells in Example 4;

[0043] Figure 7 (Top left) shows the inhibitory effects of small molecules at different concentrations and incubated for different times on MGL in Example 5; Figure 7 (Top right) is the reversible effect of the small molecule's inhibition of MGL in Example 5; Figure 7 (Lower left) is the covalent effect of the small molecule in Example 5 on the inhibition of MGL; Figure 7 (Bottom middle) shows the effect of different incubation times of small molecules on the survival rate of tumor cells in Example 5; Figure 7 (Bottom right) shows the effect of different concentrations of small molecules in Example 5 on the survival rate of tumor cells. DETAILED DESCRIPTION

[0044] The present invention is further described below in conjunction with embodiments, but the present invention is not limited thereto at all.

[0045] Example 1

[0046] The small molecule inhibitor involved is: Compound 1, the structural formula is as follows:

[0047]

[0048] The activity detection method is as follows:

[0049] 1. Construction of human MGL prokaryotic gene plasmid

[0050] The MGL gene sequence was inserted into the pET28a plasmid by restriction digestion to construct the pET28a-His-MGL plasmid, which was verified by DNA sequencing.

[0051] Human MGL protein sequence:

[0052] METGPEDPSSMPEESSPRRTPQSIPYQDLPHLVNADGQYLFCRYWKPTGTPKALIFVSHGAGEHSGRYEELARMLMGLDLLVFAHDHVGHGQSEGERMVVSDFHVFVRDVLQHVDSMQKDYPGLPVFLLGHSMGGAIAILTAAERPGHFAGMVLISP LVLANPESATTFKVLAAKVLNLVLPNLSLLGPIDSSVLSRNKTEVDIYNSDPLICRAGLKVCFGIQLLNAVSRVERALPKLTVPFLLLQGSADRLCDSKGAYLLMELAKSQDKTLKIYEGAYHVLHKELPEVTNSVFHEINMWVSQRTATAGTASPP*

[0053] 2. Expression of MGL fusion protein

[0054] The plasmid constructed in step 1 was transformed into the Escherichia coli BL21 strain by the CaCl2 method, and selected by kanamycin. Then, a single colony grown on a Luria-Bertani (LB) culture plate containing kanamycin was inoculated into a liquid LB medium containing kanamycin, and cultured at 37°C and 200 rpm until the logarithmic growth phase. Isopropylthiogalactoside (IPTG) was added to a final concentration of 0.5 mM, and induced at 37°C for 4 h, followed by collection by centrifugation;

[0055] 3. Purification of MGL fusion protein

[0056] The bacterial sludge collected in step 2 was resuspended with lysis buffer, lysed by ultrasonic method, and then the lysate was centrifuged at 4°C and 10,000 rpm, and the supernatant was retained; finally, Ni-NTA His tag protein binding filler was used for binding and purification to obtain human MGL fusion protein, and the elution buffer composition of MGL fusion protein was: 20mM Tris-HCl, pH=7.5, 100mM NaCl, 250mM imidazole;

[0057] 4. Activity test of MGL protein

[0058] Buffer: 10mM Tris-HCl (pH=7.2), 0.1mg / mL BSA, 0.01% Tween 20, DMSO: 1.5%. Add His-MGL protein with a final concentration of 10nM to each well of the 96-well plate and incubate at room temperature for 0 / 30 / 60 / 90 / 120min. After the incubation time is reached, add 2μl of 4-NPA (p-nitrophenyl acetate) with a final concentration of 200μM to each well at the same time. Set up 2 replicates and use the absorbance kinetics in the microplate reader to determine the absorption value, with a wavelength of 405nm, and detect once every 4min, for a total of 6 times, for a total of 20min.

[0059] 5. Verification of inhibitor activity

[0060] 1 μl of 10 nM His-MGL protein was added to each well of a 96-well plate, and 2 μl of small molecule solutions of different concentrations were added. After incubation at room temperature for 0 / 30 / 60 / 90 min, 2 replicates were set up. The absorbance value was determined by absorbance kinetics in an ELISA instrument with a wavelength of 405 nm. The detection was performed once every 4 min for a total of 6 times, for a total of 20 min. The inhibition rate was calculated and plotted.

[0061] 6. Verification of reversible inhibitory activity

[0062] According to the system in step 5, select the appropriate small molecule concentration and incubation time, and divide into three groups for control: the first group will incubate the single small molecule and protein for a certain period of time, then add the substrate (4-NPA) for detection; the second group will choose to amplify the concentration of small molecules and proteins by 50 times. After the incubation, take 4μl from the mixed solution and add it to 194μl Buffer, and then quickly add 2μl substrate (4-NPA) to dilute the final concentration of protein and small molecules by 50 times for detection; the incubation conditions of the third group are the same as those of the second group. When the remaining 10min of incubation is left, take 4μl of the incubation mixture and add it to 194μl Buffer, balance for 10min, and then add the substrate for detection. Set up 3 replicates; use the absorbance kinetics in the microplate reader to determine the absorption value, the wavelength is 405nm, and the detection is performed once every 4min, for a total of 6 times, for a total of 20min, calculate the inhibition rate and draw a graph.

[0063] 7. Preliminary verification of covalency by HPLC

[0064] According to the system of step 5, the total reaction volume is 200 μL, the appropriate small molecule concentration is selected, and the incubation time gradient is set. After the incubation time is reached, the substrate 4-NPA is added at a final concentration of 200 μM. After ten minutes of reaction, 200 μL of acetonitrile is immediately added to terminate the reaction, and then filtered through a 0.2 μm filter membrane. HPLC is used to determine the consumption of the substrate (4-NPA) of each sample, and the inhibition rate is calculated and plotted to determine whether the inhibition rate increases with the increase in incubation time, thereby determining whether it has certain covalent properties.

[0065] 8. Use CCK-8 to detect the effect of different incubation times of small molecules on the survival rate of tumor cells

[0066] Take MB231 cells in the logarithmic growth phase, and make a cell suspension after standard digestion treatment. After counting the cells, the concentration of the cell suspension is obtained. The cells are inoculated in a 96-well plate at a density of 15,000 cells / well at 48h and 10,000 cells / well at 72h, respectively. The cell suspension in each well is 100 μL, and the cells are placed in a 37°C incubator for overnight adherence culture. The next day, the old culture medium in each well was discarded, and the cells were treated with 100 μM culture medium (5% FBS) containing different small molecules. The control group added DMSO in the same amount as the small molecule, and the DMSO concentration was less than 0.1%. Each treatment group has 3 replicates. After drug treatment, the 96-well plate was placed in an incubator for incubation for 48h and 72h. After the drug incubation is completed, the old culture medium in each well is aspirated, and then a culture medium (5% FBS) containing 10% CCK-8 is added to each experimental well. Place in the incubator and continue incubating for 4 hours, then use an enzyme-labeled detector to detect the absorbance value (OD value) of each well, and the measurement wavelength is 450nm. Calculate the cell survival rate (%) = (OD drug-OD blank) / (OD control-OD blank) × 100%, and plot the cell survival rate as the ordinate and the logarithm of the drug concentration as the abscissa.

[0067] 9. Use CCK-8 to detect the effect of different concentrations of small molecules on tumor cell survival rate

[0068] Take MB231 cells in the logarithmic growth phase, and make a cell suspension after standard digestion treatment. After counting the cells, the concentration of the cell suspension is obtained, and the cells are inoculated in a 96-well plate at a density of 72h:10000 / well. The cell suspension in each well is 100μL, and the cells are placed in a 37℃ incubator overnight for adherent culture. The next day, the old culture medium in each well was discarded, and the cells were treated with 100μM culture medium (5% FBS) containing different concentrations of small molecules. The control group added DMSO equal to the small molecule, and the DMSO concentration was less than 0.1%. Each treatment group has 3 replicates. After drug treatment, the 96-well plate was placed in an incubator for 72h. After the drug incubation was completed, the old culture medium in each well was aspirated, and then a culture medium (5% FBS) containing 10% CCK-8 was added to each experimental well. Place in the incubator and continue incubation for 4h, and then use an enzyme-labeled detector to detect the absorbance value (OD value) of each well, and the measurement wavelength is 450nm. Calculate the cell survival rate (%) = (OD drug-OD blank) / (OD control-OD blank) × 100%, and plot the cell survival rate as the ordinate and the logarithm of the drug concentration as the abscissa.

[0069] The relevant test results are as follows:

[0070] Figure 2 This is the verification of the activity of MGL protein and 4-NPA in this example. It can be seen from the figure that the activity is relatively stable within 2 hours at the protein concentration, and the detection system is relatively reliable.

[0071] Figure 3 (Upper left) shows that as the concentration of small molecule compound 1 increases and the incubation time increases, the inhibition rate increases, indicating that the inhibition of compound 1 is time-dependent and concentration-dependent. Figure 3 (Upper right) shows that after compound 1 was incubated at high concentration and diluted, the inhibitory effect was not similar to the single-drug effect, indicating that the inhibition of compound 1 was irreversible. Figure 3 (Lower left) HPLC detection shows that the inhibitory effect of compound 1 increases with time, indicating that it has certain covalent properties. Figure 3 (Bottom middle) shows that the small molecules described in this example can effectively reduce the survival rate of tumor cells. Figure 3 (Bottom right) shows that as the concentration of small molecules increases, the survival rate of tumor cells gradually decreases.

[0072] Example 2

[0073] The small molecule inhibitor involved is: Compound 2, the structure of which is shown below:

[0074]

[0075] The activity detection method is the same as in Example 1.

[0076] Figure 4(Upper left) shows that as the concentration of small molecule compound 2 increases and the incubation time increases, the inhibition rate increases, indicating that the inhibition of compound 2 is time-dependent and concentration-dependent. Figure 4 (Upper right) shows that after compound 2 was incubated at high concentration and diluted, the inhibitory effect was not similar to the single-drug effect, indicating that the inhibition of compound 2 was irreversible. Figure 4 (Lower left) HPLC detection shows that the inhibitory effect of compound 2 increases with time, indicating that it has certain covalent properties. Figure 4 (Bottom middle) shows that the small molecules described in this example can effectively reduce the survival rate of tumor cells. Figure 4 (Bottom right) shows that as the concentration of small molecules increases, the survival rate of tumor cells gradually decreases.

[0077] Example 3

[0078] The small molecule inhibitor involved is: Compound 3, the structure of which is shown below:

[0079]

[0080] The activity detection method is the same as in Example 1.

[0081] Figure 5 (Upper left) shows that as the concentration of small molecule compound 3 increases and the incubation time increases, the inhibition rate increases, indicating that the inhibition of compound 3 is time-dependent and concentration-dependent. Figure 5 (Upper right) shows that after compound 3 was incubated at high concentration and diluted, the inhibitory effect was not similar to the single-drug effect, indicating that the inhibition of compound 3 was irreversible. Figure 5 (Lower left) HPLC detection shows that the inhibitory effect of compound 3 increases with time, indicating that it has certain covalent properties. Figure 5 (Bottom middle) shows that the small molecules described in this example can effectively reduce the survival rate of tumor cells. Figure 5 (Bottom right) shows that as the concentration of small molecules increases, the survival rate of tumor cells gradually decreases.

[0082] Example 4

[0083] The small molecule inhibitor involved is: Compound 4, the structure of which is shown below:

[0084]

[0085] The activity detection method is the same as in Example 1.

[0086] Figure 6 (Upper left) shows that as the concentration of small molecule compound 4 increases and the incubation time increases, the inhibition rate increases, indicating that the inhibition of compound 4 is time-dependent and concentration-dependent. Figure 6(Upper right) shows that after compound 4 was incubated at high concentration and diluted, the inhibitory effect was not similar to the single-drug effect, indicating that the inhibition of compound 4 was irreversible. Figure 6 (Lower left) HPLC detection shows that the inhibitory effect of compound 4 increases with time, indicating that it has certain covalent properties. Figure 6 (Bottom middle) shows that the small molecules described in this example can effectively reduce the survival rate of tumor cells. Figure 6 (Bottom right) shows that as the concentration of small molecules increases, the survival rate of tumor cells gradually decreases.

[0087] Example 5

[0088] The small molecule inhibitor involved is: Compound 5, the structure of which is shown below:

[0089]

[0090] The activity detection method is the same as in Example 1.

[0091] Figure 7 (Upper left) shows that as the concentration of small molecule compound 5 increases and the incubation time increases, the inhibition rate increases, indicating that the inhibition of compound 5 is time-dependent and concentration-dependent. Figure 7 (Upper right) shows that after compound 5 was incubated at high concentration and diluted, the inhibitory effect was not similar to the single-drug effect, indicating that the inhibition of compound 5 was irreversible. Figure 7 (Lower left) shows that the inhibitory effect of compound 5 did not increase with time as detected by HPLC, indicating that it may not have covalent properties. Figure 7 (Bottom middle) shows that the small molecules described in this example can effectively reduce the survival rate of tumor cells. Figure 7 (Bottom right) shows that as the concentration of small molecules increases, the survival rate of tumor cells gradually decreases.

[0092] The above description is only a preferred specific implementation manner of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention should be included in the scope of protection of the invention.

Claims

1. Use of a small molecule inhibitor in the preparation of a drug for inhibiting monoacylglycerol lipase, characterized in that: The structure of this small molecule is as follows: Among them, R is -C≡N.

2. Use of the small molecule inhibitor according to claim 1 in the preparation of a drug for inhibiting monoacylglycerol lipase, characterized in that: The monoacylglycerol lipase is human monoacylglycerol lipase.

3. Use of the small molecule inhibitor according to claim 1 in the preparation of a drug for inhibiting monoacylglycerol lipase, characterized in that: The molar concentration ratio of the small molecule inhibitor in the final reaction volume is in the range of small molecule inhibitor:protein=50:1-100000:1.